Joseph Sliman

Age-Specific Prevalence of Epstein–Barr Virus Infection Among Individuals Aged 6–19 Years in the United States and Factors Affecting Its Acquisition

Henry H. Balfour, Frangiscos Sifakis, Joseph Sliman et al. · The Journal of Infectious Diseases · 2013 · 257 citations

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

John F. Kokai‐Kun, Tracey Roberts, Olivia Coughlin et al. · The Lancet Infectious Diseases · 2019 · 82 citations

Antimicrobial Susceptibility, Antibiotics, Phase 2B +11

Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age

Elissa Malkin, Ram Yogev, Nazha Abughali et al. · PLoS ONE · 2013 · 80 citations · Full text

Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection

Michael Kaleko, J. Andrew Bristol, Steven Hubert et al. · Anaerobe · 2016 · 68 citations · Full text

Dysbiosis, Antibiotic-mediated Damage, Complex Ecosystem +16

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

John F. Kokai‐Kun, Tracey Roberts, Olivia Coughlin et al. · Antimicrobial Agents and Chemotherapy · 2017 · 63 citations · Full text